| Patient Communication: The Surgeon’s Role |
|
- Interpretation of Breast Cancer Biomarkers
- Individualized Benefits and Side Effects of Systemic Therapy
- Promises and Limitations of Targeted Therapy
- Advocacy in Cancer Care and Research
- Learning How to Counsel Our Patients
1 AMA
PRA Category 1 Credit™
Expiration date: June 6, 2009 |
| Clinical Colorectal Cancer Vol. 7 Suppl. 1 |
|
- New Developments in Targeted Treatment Strategies for Colorectal Cancer
1.25 AMA
PRA Category 1 Credits™
Expiration date: May 27, 2009 |
| Angiogenesis in Oncology Vol. 2 No. 6 |
|
- Current Status of Antiangiogenesis Therapy of Colorectal Cancer: Timing and Duration of Therapy
- Combined Modality Therapy in Early-Stage Non–Small-Cell Lung Cancer: The Potential and Future Role of Antiangiogenic Agents
- Targeting the Tumor Microenvironment
1 AMA
PRA Category 1 Credit™
Expiration date: January 17, 2009 |
| Oncology Consultations Vol. 4 No. 13 |
|
- Combination Biologic Therapy and Chemotherapy for Metastatic Colorectal Cancer
1 AMA
PRA Category 1 Credit™
Expiration date: January 17, 2009 |
| Clinical Colorectal Cancer Vol. 6, Suppl. 2 |
|
- Current Practice and Progress with Targeted Therapies in Colorectal Cancer
1 AMA
PRA Category 1.5 Credits™
Expiration date: January 31, 2009 |
| Advances in Colon Cancer Vol. 8, No. 2 |
|
- Preclinical and Early Clinical Data on TRAIL in Colon Cancer
- Colon Cancer Pathogenesis and the Death Receptor Pathway
1 AMA
PRA Category 1 Credit™
Expiration date: December 22, 2008 |
| Oncology Consultations Vol. 4, No. 11 |
|
- Combination Biologic Therapy and Chemotherapy for Metastatic CRC
- Dual Biologics in Advanced CRC: CALGB/SWOG 80405 Trial
- Final Results of the BOND-2 Trial
- Chemotherapy-Associated Liver Toxicity
1 AMA
PRA Category 1 Credit™
Expiration date: December 22, 2008 |
| Angiogenesis in Oncology Vol. 2, No.
5 |
|
- Incorporating Antiangiogenic Agents Into the Perioperative
Setting for Colorectal Cancer
- Biology and Management of Hypertension and Other Class-Effect
Toxicities Related to antiangiogenic Therapy
- Novel Avenues in Antivascular Tumor Therapy
1 AMA
PRA Category 1 Credit™
Expiration date: December 7, 2008 |
| Impact of EGFR-Targeted Therapies on Management of Carcinoma of the Colon and Rectum |
|
- Predictive and Prognostic Value of EGFR Signaling Molecules in the Management of Colorectal Cancer
- Clinical Trial Data on Panitumumab in Metastatic Colorectal Cancer
- Clinical Trials of Epidermal Growth Factor Receptor Inhibitors in Noncolorectal Gastrointestinal Malignancies
- Minimizing Acute and Chronic Toxicities Associated With Epidermal Growth Factor Receptor Antibodies
- Dual Blockade of the Epidermal Growth Factor Receptor Pathway for the Treatment of Advanced Colorectal Cancer
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008 |
